Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Current Taxes (2018 - 2025)

Historic Current Taxes for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q4 2025 value amounting to $963.7 million.

  • Takeda Pharmaceutical's Current Taxes fell 811.74% to $963.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $963.7 million, marking a year-over-year decrease of 811.74%. This contributed to the annual value of $876.4 million for FY2025, which is 1499.62% up from last year.
  • Per Takeda Pharmaceutical's latest filing, its Current Taxes stood at $963.7 million for Q4 2025, which was down 811.74% from $834.2 million recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Current Taxes peaked at $1.9 billion during Q2 2022, and registered a low of $741.6 million during Q1 2024.
  • In the last 5 years, Takeda Pharmaceutical's Current Taxes had a median value of $1.2 billion in 2022 and averaged $1.3 billion.
  • Within the past 5 years, the most significant YoY rise in Takeda Pharmaceutical's Current Taxes was 3787.57% (2024), while the steepest drop was 5778.45% (2024).
  • Takeda Pharmaceutical's Current Taxes (Quarter) stood at $1.6 billion in 2021, then decreased by 18.09% to $1.3 billion in 2022, then crashed by 43.07% to $760.7 million in 2023, then skyrocketed by 37.88% to $1.0 billion in 2024, then decreased by 8.12% to $963.7 million in 2025.
  • Its last three reported values are $963.7 million in Q4 2025, $834.2 million for Q3 2025, and $1.0 billion during Q2 2025.